Jupiter Neurosciences (NASDAQ:JUNS) Shares Climb 12.7% – Time to Buy?

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) shares traded up 12.7% during trading on Monday. The stock traded as high as $2.43 and last traded at $2.31. Approximately 31,755 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 69,251 shares. The stock had previously closed at $2.05.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Jupiter Neurosciences Trading Up 1.2%

The firm has a 50-day moving average of $2.97 and a two-hundred day moving average of $20.16.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its quarterly earnings data on Friday, August 14th. The company reported ($5.06) EPS for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.40 million.

Institutional Trading of Jupiter Neurosciences

An institutional investor recently raised its stake in Jupiter Neurosciences stock. Vestor Capital LLC boosted its stake in shares of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) by 144,607.2% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 970,985 shares of the company’s stock after purchasing an additional 970,314 shares during the period. Vestor Capital LLC owned about 2.68% of Jupiter Neurosciences worth $365,000 at the end of the most recent reporting period.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc (NASDAQ:JUNS) is a clinical-stage biotechnology company focused on developing therapies for diseases associated with neuroinflammation. The company’s research is centered on small-molecule drug candidates intended to address inflammatory processes affecting the central nervous system.

Jupiter Neurosciences’ lead product candidate, JNS-101, is an orally administered, brain-penetrant compound being developed for its potential anti-inflammatory and neuroprotective effects.